Trade Elicit Therapeutics Inc. - ELTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1810 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.6895 |
| Open | 4.7495 |
| 1-Year Change | -42.95% |
| Day's Range | 4.7495 - 5.2595 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2025 | 5.0295 | 0.2700 | 5.67% | 4.7595 | 5.2595 | 4.7495 |
| Apr 21, 2025 | 4.6895 | -0.1000 | -2.09% | 4.7895 | 4.9295 | 4.6095 |
| Apr 17, 2025 | 4.7495 | -0.0800 | -1.66% | 4.8295 | 4.8895 | 4.6995 |
| Apr 16, 2025 | 4.8395 | -0.1200 | -2.42% | 4.9595 | 5.0995 | 4.6895 |
| Apr 15, 2025 | 4.9595 | 0.2600 | 5.53% | 4.6995 | 4.9995 | 4.6995 |
| Apr 14, 2025 | 4.7995 | 0.2100 | 4.58% | 4.5895 | 5.1395 | 4.5895 |
| Apr 11, 2025 | 4.9895 | 0.0000 | 0.00% | 4.9895 | 5.1095 | 4.9795 |
| Apr 10, 2025 | 4.9995 | 0.0000 | 0.00% | 4.9995 | 5.1295 | 4.9895 |
| Apr 9, 2025 | 5.1995 | 0.0100 | 0.19% | 5.1895 | 5.4395 | 4.4895 |
| Apr 8, 2025 | 5.0895 | 0.0000 | 0.00% | 5.0895 | 5.6995 | 5.0895 |
| Apr 7, 2025 | 5.1795 | -0.4100 | -7.34% | 5.5895 | 5.6995 | 5.1395 |
| Apr 4, 2025 | 5.8495 | 0.4800 | 8.94% | 5.3695 | 6.0795 | 5.0895 |
| Apr 3, 2025 | 5.3795 | 0.4400 | 8.91% | 4.9395 | 5.6995 | 4.9395 |
| Apr 2, 2025 | 5.1495 | 0.1600 | 3.21% | 4.9895 | 5.3895 | 4.7495 |
| Apr 1, 2025 | 4.9395 | -1.0500 | -17.53% | 5.9895 | 5.9895 | 4.8295 |
| Mar 31, 2025 | 6.1395 | -1.2500 | -16.92% | 7.3895 | 7.3895 | 6.1395 |
| Mar 28, 2025 | 7.7695 | 0.0800 | 1.04% | 7.6895 | 8.0395 | 7.5895 |
| Mar 27, 2025 | 7.6495 | -0.3400 | -4.26% | 7.9895 | 7.9895 | 7.4795 |
| Mar 26, 2025 | 7.9895 | -0.1500 | -1.84% | 8.1395 | 8.1895 | 7.9895 |
| Mar 25, 2025 | 8.2895 | 0.0000 | 0.00% | 8.2895 | 8.3895 | 8.1795 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com